IncellDx, Inc., a Menlo Park, CA-based molecular diagnostics company focused on the detection and monitoring of life threatening diseases such as hepatitis, HIV/AIDs, cervical cancer, and organ transplant rejection, has closed a $3m Series A funding round.The funds will be used to to advance the commercialization of IncellDx™ products and to start the US clinical trial for HPV OncoTect®, a E6, E7 mRNA test which is expected to detect and quantify the cellular oncogenes responsible for triggering progression to cervical cancer.
The test directly addresses the problem of the lack of specificity of existing screening products in the US High Risk HPV testing market, which is estimated to be $300m and growing at an annual rate of 14%.
The investors in the round remained undisclosed.
FinSMEs
08/06/2010